Antiviral medications work by interfering with the ability of the COVID-19 virus to replicate inside the body. This lowers the “viral load,” which is the amount of virus doctors find in your body. This can help reduce the severity of COVID-19 symptoms and shorten the length of the illness.

This table is for informational purposes only. Treatments require a prescription and should be guided by a patient’s healthcare team.

### Paxlovid® (nirmatrelvir and ritonavir tablets)

Important note: Paxlovid may impair the efficacy and safety of certain cancer medications. It should be used with the guidance of your oncologist.

| Authorized for | Treatment of mild-to-moderate COVID-19 confirmed by a positive COVID-19 test in non-hospitalized patients who are at high risk of progression to severe infection (such as blood cancer patients and survivors) Paxlovid treatment is not  
• For use in preventing COVID-19 infection  
• Authorized for use longer than 5 consecutive days |
|---|---|
| Ages | Adults 18 years and older  
Children 12 and up who weigh at least 88 pounds |
| Activity against Omicron | Effective against the Omicron variant in preliminary laboratory studies and likely to be effective in patients\(^2\)\(^3\) |
| Dosing/Timing | • Treatment should begin as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset  
• Three tablets (2 nirmatrelvir and 1 ritonavir) taken together twice daily for 5 days  
• Can be taken with or without food |
| Manufacturer | Pfizer  
[Click here](https://www.pfizer.com) to read the manufacturer’s Fact Sheet for Patients, Parents and Caregivers. |

### Lagevrio® (molnupiravir)

| Authorized for | Treatment of mild-to-moderate COVID-19 confirmed by a positive COVID-19 test in non-hospitalized patients who are at high risk of progression to severe infection (such as blood cancer patients and survivors) Lagevrio treatment is not  
• For use in preventing COVID-19 infection  
• Authorized for use longer than 5 consecutive days |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Ages</td>
<td>Adults 18 years and older</td>
</tr>
<tr>
<td>Activity against Omicron</td>
<td>Effective against the Omicron variant in preliminary laboratory studies and likely to be effective in patients(^2)(^3)</td>
</tr>
</tbody>
</table>
| Dosing/Timing | • Treatment should begin as soon as possible after COVID-19 diagnosis and within 5 days of symptom onset  
• Four capsules taken every 12 hours for 5 days  
• Can be taken with or without food |
| Manufacturer | Merck & Co., Inc.  
[Click here](https://www.merck.com) to read the manufacturer’s Fact Sheet for Patients, Parents and Caregivers. |

Continued
# Antiviral Treatments for COVID-19 in Non-Hospitalized Patients

## Veklury® (remdesivir)

| Authorized for | Treatment of mild-to-moderate COVID-19 confirmed by a positive COVID-19 test in non-hospitalized patients who are at high risk of progression to severe infection (such as blood cancer patients and survivors) |
| Ages | Adults 18 years and older  
Pediatric patients 28 days of age and older weighing at least 3 kg (approximately 6.6 pounds) |
| Activity against Omicron | Effective against the Omicron variant in multiple laboratory studies and likely to be effective in patients with COVID-19<sup>6</sup> |
| Dosing/Timing | Remdesivir requires intravenous (IV) infusions or injections at a healthcare facility. It should be started as soon as possible after symptoms begin  
Treatment must begin within seven days of symptom onset and lasts for three days |
| Manufacturer | Gilead  
[Click here](#) to read the manufacturer’s Patient Information sheet. |

1. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid  
3. Vangeel L et al. Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern.  